Irinotecan Hydrochloride Patent Expiration
Irinotecan Hydrochloride is used for treating metastatic colorectal cancer in combination with 5-fluorouracil, leucovorin, and irinotecan. It was first introduced by Pfizer Inc
Irinotecan Hydrochloride Patents
Given below is the list of patents protecting Irinotecan Hydrochloride, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Onivyde | US10456360 | Stabilizing camptothecin pharmaceutical compositions | Oct 15, 2036 | Ipsen |
| Onivyde | US10993914 | Stabilizing camptothecin pharmaceutical compositions | Oct 15, 2036 | Ipsen |
| Onivyde | US12059497 | Stabilizing camptothecin pharmaceutical compositions | Oct 15, 2036 | Ipsen |
| Onivyde | US11344552 | Methods for treating metastatic pancreatic cancer using combination therapies comprising liposomal irinotecan and oxaliplatin | Aug 19, 2036 | Ipsen |
| Onivyde | US10980795 | Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan | Jun 12, 2033 | Ipsen |
| Onivyde | US11369597 | Methods for treating pancreatic cancer using combination therapies | Jun 12, 2033 | Ipsen |
| Onivyde | US9339497 | Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan | Jun 12, 2033 | Ipsen |
| Onivyde | US9364473 | Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan | Jun 12, 2033 | Ipsen |
| Onivyde | US9452162 | Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan | Jun 12, 2033 | Ipsen |
| Onivyde | US9492442 | Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan | Jun 12, 2033 | Ipsen |
| Onivyde | US9717724 | Methods for treating pancreatic cancer using combination therapies | Jun 12, 2033 | Ipsen |
| Onivyde | US8147867 | Liposomes useful for drug delivery | Aug 29, 2028 | Ipsen |
| Onivyde | US8329213 | Liposomes useful for drug delivery | Jan 06, 2027 | Ipsen |
| Onivyde | US10722508 | Liposomes useful for drug delivery |
May 02, 2025
(Expired) | Ipsen |
| Onivyde | US8703181 | Liposomes useful for drug delivery |
May 02, 2025
(Expired) | Ipsen |
| Onivyde | US8992970 | Liposomes useful for drug delivery |
May 02, 2025
(Expired) | Ipsen |
| Onivyde | US9724303 | Liposomes useful for drug delivery |
May 02, 2025
(Expired) | Ipsen |
| Onivyde | US9730891 | Liposomes useful for drug delivery |
May 02, 2025
(Expired) | Ipsen |
| Onivyde | US9782349 | Liposomes useful for drug delivery |
May 02, 2025
(Expired) | Ipsen |
| Camptosar |
US6794370 (Pediatric) | Method for treating cancer using camptothecin derivatives and 5-fluorouracil |
Nov 01, 2020
(Expired) | Pfizer Inc |
| Camptosar |
US6403569 (Pediatric) | Method for treating cancer using camptothecin derivatives and 5-fluorouracil |
Oct 28, 2020
(Expired) | Pfizer Inc |
| Camptosar | US6794370 | Method for treating cancer using camptothecin derivatives and 5-fluorouracil |
May 01, 2020
(Expired) | Pfizer Inc |
| Camptosar | US6403569 | Method for treating cancer using camptothecin derivatives and 5-fluorouracil |
Apr 28, 2020
(Expired) | Pfizer Inc |
Irinotecan Hydrochloride's Family Patents
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List